Axon Neuroscience SE
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia (NCT03174886) | Axon Neuroscience SE | 2017-07-31 |
| 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (NCT02579252) | Axon Neuroscience SE | 2016-03-01 |
| 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (NCT02031198) | Axon Neuroscience SE | 2014-01-01 |
| Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease (NCT01850238) | Axon Neuroscience SE | 2013-05-01 |
Track Axon Neuroscience SE automatically
Every clearance here is in the API, with alerts when new ones post.